Lean Life Science and Cancer Research Horizons launch new Oncology Development Programme, ODP2

Do you have an emerging oncology innovation that have the potential to improve diagnosis and treatment of cancer?

Lean Life Science and Cancer Research Horizons have launched a new Oncology Development Programme focused on accelerating high impact novel cancer innovations. Called ODP2, it is a fully-funded programme to identify and accelerate novel oncology innovations, including therapeutics, diagnostics, digital tech, and medical devices, into commercially attractive assets.

Open to the UK-based academic community and early-stage companies, the programme is supported by unique insights from a collaboration of leading global pharma companies, CROs, and subject matter experts in residence from across the global oncology R&D ecosystem.

ODP2 will Identify, de-risk and catalyse commercially viable UK-based oncology innovations to improve diagnosis and treatment of cancer and accelerate the translation of emerging cancer research for patient benefit.

Participation in ODP2 will give the next big UK-based breakthroughs in oncology access to bespoke expert scientific review, clinical study design, technical gap analysis, financial / business value modelling and integrated project planning.

If you or someone in your network has an innovations that would benefit from participation in ODP2 please share this information.

Full details of ODP2 can be found here, along with dates of Q&A webinars.